profit from every $100 of sales.
$0$100
Gain Therapeutics
$1.04-3.70% today
-65.2% in 1 year
1-year low $0.961-year high $4.18
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Gain Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $140,108 in 2022 to $0 in 2025, with -$20.2 million of profit last year.
SalesProfit
Gain Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Gain Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Gain Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -18 | -22 | -20 | -19 | |
| -18 | -22 | -20 | -19 | |
| -18 | -22 | -20 | -20 | |
| -1.48 | -1.71 | -0.89 | -0.61 | |
| – | – | – | – | |
| -12,688.1% | -40,328.3% | – | – | |
| -12,555.1% | -40,354.3% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 24 | 19 | 12 | 23 |
| Cash | 7 | 12 | 10 | 21 |
| Total debt | 1 | 1 | 1 | 1 |
| Total liabilities | 5 | 6 | 5 | 4 |
| 19 | 13 | 7 | 19 | |
| 12 | 13 | 23 | 33 | |
| -69.7% | -129.2% | -201.1% | -76.6% | |
| -93.2% | -177.0% | -278.1% | -108.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -19 | -19 | -18 | |
| 0 | 0 | 0 | – | |
| -15 | -19 | -19 | -18 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 3 | 2 | 2 |
Valuation
- –
- –
- –
- 3.2×
- 839.2×
- –
- –
- -40.8%
- -48.1%
- 0.0%
Profitability
- 0.0%
- -40,328.3%
- -40,354.3%
- 0.0%
- -95.0%
- -129.8%
- -237.5%
- -88.4%
- -96.1%
- –
Growth
- −60.6%
- –
- +2.3%
- –
- +34.2%
Financial health
- -0.5×
- 0.04
- 3.2%
- –
- 6.63
- 6.63
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 1%of 888
Bottom 1%of 987
What analysts expect
- Average price target
- $9.00
- Range
- $8.00 – $10.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.13 | -0.13 | +0.0% |
| Mar 26, 2026 | -0.11 | -0.14 | +21.4% |
| Nov 12, 2025 | -0.15 | -0.15 | +0.0% |
| Aug 12, 2025 | -0.19 | -0.17 | −11.8% |
| May 14, 2025 | -0.16 | -0.16 | +0.0% |
| Mar 27, 2025 | -0.11 | -0.18 | +38.9% |
| Nov 14, 2024 | -0.17 | -0.23 | +26.1% |
| Aug 8, 2024 | -0.42 | -0.31 | −35.5% |
News
BW LPG sells vessel BW Mistral for $104M, expects $37M book gainSeeking Alpha · Nov 13, 2026AAPL, GOOG Stocks Gain Overnight As NVDA Slides: Are Retail Investors Rotating Into Traditional Tech Amid Leadership Turmoil?Yahoo Finance · Nov 12, 2026Sandisk’s stock just staged a big gain. Here’s how it could march even higher.MarketWatch · Nov 11, 2026AI chip exports to China and oversight bills gain momentum in CongressYahoo Finance · Nov 10, 2026Monolithic Power Systems rises 17%, its fifth gain in seven sessionsSeeking Alpha · Nov 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
40No pass
Philip Fisher
34No pass
Peter Lynch
11No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
28No pass
Questions about Gain Therapeutics
Is Gain Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Gain Therapeutics AI analysis
What does Gain Therapeutics do?
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. It is in Biotechnology.
Does Gain Therapeutics pay a dividend?
No. Gain Therapeutics does not pay a dividend at the moment.
Is Gain Therapeutics stock halal?
No. Gain Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 45% of its market value, at or above the 33% limit. How we check
How has Gain Therapeutics stock done over the past year?
Down 65.2% over the past twelve months, to $1.04. It traded between $0.96 and $4.18 and is 75.1% below its high.
Who are Gain Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Gain Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.